Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma

Pleural mesothelioma is a lung diffuse tumor, whose complete resection is unlikely. Consequently, metastases reappear where the primary tumor was removed. This paper illustrates the orphan medicine designation procedure of an intracavitary cisplatin film and related pharmaceutical development aspect...

Full description

Bibliographic Details
Main Authors: Sabrina Banella, Eride Quarta, Paolo Colombo, Fabio Sonvico, Antonella Pagnoni, Fabrizio Bortolotti, Gaia Colombo
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Pharmaceutics
Subjects:
Online Access:https://www.mdpi.com/1999-4923/13/3/362
id doaj-79bd3c0d70fc4eaf96ac355f34081ce4
record_format Article
spelling doaj-79bd3c0d70fc4eaf96ac355f34081ce42021-03-10T00:03:35ZengMDPI AGPharmaceutics1999-49232021-03-011336236210.3390/pharmaceutics13030362Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant MesotheliomaSabrina Banella0Eride Quarta1Paolo Colombo2Fabio Sonvico3Antonella Pagnoni4Fabrizio Bortolotti5Gaia Colombo6Department of Life Sciences and Biotechnology, University of Ferrara, Via Fossato di Mortara 17/19, 44121 Ferrara, ItalyFood and Drug Department, University of Parma, Parco Area delle Scienze 27A, 43124 Parma, ItalyPlumeStars srl, c/o Food & Drug Department, Parco Area delle Scienze 27A, 43124 Parma, ItalyFood and Drug Department, University of Parma, Parco Area delle Scienze 27A, 43124 Parma, ItalyDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari 46, 44121 Ferrara, ItalyDepartment of Life Sciences and Biotechnology, University of Ferrara, Via Fossato di Mortara 17/19, 44121 Ferrara, ItalyDepartment of Life Sciences and Biotechnology, University of Ferrara, Via Fossato di Mortara 17/19, 44121 Ferrara, ItalyPleural mesothelioma is a lung diffuse tumor, whose complete resection is unlikely. Consequently, metastases reappear where the primary tumor was removed. This paper illustrates the orphan medicine designation procedure of an intracavitary cisplatin film and related pharmaceutical development aspects requested by the European Medicines Agency (EMA) in its Scientific Advice. Since cisplatin pharmacokinetics from the implanted film in sheep resulted substantially modified compared to intravenous administration, the formation of a cisplatin/hyaluronan complex had been hypothesized. Here, the interaction between sodium hyaluronate (NaHA) and cisplatin (CisPt) was demonstrated. Size exclusion chromatography qualitatively evidenced the complex in the film-forming mixture, only showing the NaHA peak. Atomic absorption spectroscopy of the corresponding fraction revealed platinum, confirming the interaction. Reverse phase HPLC quantified about 5% free cisplatin in the film-forming mixture, indirectly meaning that 95% was complexed. Finally, a study of CisPt release from the film assessed how CisPt/NaHA complex affected drug availability. In water, a medium without chloride ions, there was no release and the film remained intact for 48 h and longer, whereas the placebo film dissolved in 15 min. In 0.9% NaCl medium, the film became more soluble, dissolving within 3–4 h. However, cisplatin release was still controlled by the existing complex in solution until chloride ions displaced it. While the film modified its dissolution with aging, CisPt release remained unaffected (90% released in 48 h).https://www.mdpi.com/1999-4923/13/3/362cisplatinsodium hyaluronatecomplexfilmintracavitaryintrapleural
collection DOAJ
language English
format Article
sources DOAJ
author Sabrina Banella
Eride Quarta
Paolo Colombo
Fabio Sonvico
Antonella Pagnoni
Fabrizio Bortolotti
Gaia Colombo
spellingShingle Sabrina Banella
Eride Quarta
Paolo Colombo
Fabio Sonvico
Antonella Pagnoni
Fabrizio Bortolotti
Gaia Colombo
Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma
Pharmaceutics
cisplatin
sodium hyaluronate
complex
film
intracavitary
intrapleural
author_facet Sabrina Banella
Eride Quarta
Paolo Colombo
Fabio Sonvico
Antonella Pagnoni
Fabrizio Bortolotti
Gaia Colombo
author_sort Sabrina Banella
title Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma
title_short Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma
title_full Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma
title_fullStr Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma
title_full_unstemmed Orphan Designation and Cisplatin/Hyaluronan Complex in an Intracavitary Film for Malignant Mesothelioma
title_sort orphan designation and cisplatin/hyaluronan complex in an intracavitary film for malignant mesothelioma
publisher MDPI AG
series Pharmaceutics
issn 1999-4923
publishDate 2021-03-01
description Pleural mesothelioma is a lung diffuse tumor, whose complete resection is unlikely. Consequently, metastases reappear where the primary tumor was removed. This paper illustrates the orphan medicine designation procedure of an intracavitary cisplatin film and related pharmaceutical development aspects requested by the European Medicines Agency (EMA) in its Scientific Advice. Since cisplatin pharmacokinetics from the implanted film in sheep resulted substantially modified compared to intravenous administration, the formation of a cisplatin/hyaluronan complex had been hypothesized. Here, the interaction between sodium hyaluronate (NaHA) and cisplatin (CisPt) was demonstrated. Size exclusion chromatography qualitatively evidenced the complex in the film-forming mixture, only showing the NaHA peak. Atomic absorption spectroscopy of the corresponding fraction revealed platinum, confirming the interaction. Reverse phase HPLC quantified about 5% free cisplatin in the film-forming mixture, indirectly meaning that 95% was complexed. Finally, a study of CisPt release from the film assessed how CisPt/NaHA complex affected drug availability. In water, a medium without chloride ions, there was no release and the film remained intact for 48 h and longer, whereas the placebo film dissolved in 15 min. In 0.9% NaCl medium, the film became more soluble, dissolving within 3–4 h. However, cisplatin release was still controlled by the existing complex in solution until chloride ions displaced it. While the film modified its dissolution with aging, CisPt release remained unaffected (90% released in 48 h).
topic cisplatin
sodium hyaluronate
complex
film
intracavitary
intrapleural
url https://www.mdpi.com/1999-4923/13/3/362
work_keys_str_mv AT sabrinabanella orphandesignationandcisplatinhyaluronancomplexinanintracavitaryfilmformalignantmesothelioma
AT eridequarta orphandesignationandcisplatinhyaluronancomplexinanintracavitaryfilmformalignantmesothelioma
AT paolocolombo orphandesignationandcisplatinhyaluronancomplexinanintracavitaryfilmformalignantmesothelioma
AT fabiosonvico orphandesignationandcisplatinhyaluronancomplexinanintracavitaryfilmformalignantmesothelioma
AT antonellapagnoni orphandesignationandcisplatinhyaluronancomplexinanintracavitaryfilmformalignantmesothelioma
AT fabriziobortolotti orphandesignationandcisplatinhyaluronancomplexinanintracavitaryfilmformalignantmesothelioma
AT gaiacolombo orphandesignationandcisplatinhyaluronancomplexinanintracavitaryfilmformalignantmesothelioma
_version_ 1724227243003084800